hit counter
Aerie Pharmaceuticals, Inc. (AERI) Stock News Sentiment & Price - Sentifly
AERI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aerie Pharmaceuticals, Inc. (AERI)

USA
Drug Manufacturers - Major
NASDAQ
AERI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AERI Latest news
Business Wire
Neutral
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
2021-10-21 16:01

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie's glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase. The slide presentation provides an update on Aerie's franchise growth in the United States, as well as progress toward market entry in Europe and Japan. The slide presentation from today's event

Business Wire
Neutral
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
2021-10-12 06:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (“netarsudil 0.02%”) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil 0.4%”). The results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure (“IOP”) at week

Business Wire
Neutral
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
2021-10-07 16:01

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie's retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aerie's proprietary PRINT® drug delivery platform and retina product candidates AR-1105 (dexamethasone implant, Phase 3 ready), AR-13503 (Rho kinase/Protei

Business Wire
Neutral
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
2021-10-06 07:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists in San Antonio, Texas. The presentation entitled “Phase 2 Study of Two Formulations of AR-1105 in Macular Ede

Business Wire
Neutral
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
2021-09-27 07:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief R&D Officer, will participate in a fireside discussion at the

Business Wire
Neutral
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
2021-09-21 06:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves as the Company's Chairman and Chief Executive Officer or as a director of the Company. Consistent with the succession plan in place, the Company's Board of Directors has appointed Benjamin F. McGraw, III, Pharm.D. a

Business Wire
Neutral
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
2021-09-20 06:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie's Vice President of Research and Discovery. Dr. Pacyniak will ove

Zacks Investment Research
Negative
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
2021-09-16 12:59

Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.

Business Wire
Neutral
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
2021-09-15 16:01

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye diseas

Business Wire
Neutral
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
2021-09-13 06:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Carolyn McAuliffe, Senior Director, Communications, reporting to Tad Heitmann, Aerie's Vice President of Marketing. Ms. McAuliffe will be responsible for the develo

Loading more news...